CLINICAL, PARACLINICAL FEATURES AND TREATMENT OUTCOMES OF CHILDREN WITH MYCOPLASMA PNEUMONIAE PNEUMONIA AT PEDIATRIC DEPARTMENT, TAM ANH GENERAL HOSPITAL, HANOI, 2023-2024
Main Article Content
Abstract
Objectives: To describe the clinical characteristics, paraclinical findings, and treatment outcomes of children with Mycoplasma pneumoniae (M. pneumoniae) pneumonia at the Pediatric Department, Tam Anh General Hospital, Hanoi, during 2023–2024.
Methods: A retrospective descriptive study was conducted on 346 hospitalized children aged 3 months to 15 years who were diagnosed with M. pneumoniae pneumonia and treated at Tam Anh General Hospital, Hanoi, between January 1, 2023 and December 31, 2024.
Results: Among the 346 patients, the mean age was 4.18 ± 2.26 years, with children aged 1–4 years accounting for the largest proportion (64.2%). Cases occurred throughout the year, with a marked peak from May to July (53.7%). The most common clinical manifestations were cough (100%) and fever (81.8%), whereas 30.3% of patients had normal lung auscultation findings. Most patients had an oxygen saturation (SpO2) ≥95% on admission (93.1%). Chest radiography most commonly showed alveolar infiltrates (48.8%), while lung ultrasound detected pulmonary consolidation in 68.2% of the examined patients. Elevated C-reactive protein (CRP) and leukocytosis were observed in 71.1% and 46.8% of patients, respectively. Among patients who underwent lactate dehydrogenase (LDH) measurement, 94.1% had elevated LDH levels. Macrolides were used as the initial antibiotic therapy in 97.7% of patients; however, 15.6% required switching to quinolones because of an inadequate clinical response. The overall treatment success rate was 98.8%, with a mean hospital stay of 5.3 ± 2.3 days, and no deaths were recorded.
Conclusions: Mycoplasma pneumoniae pneumonia at Tam Anh General Hospital predominantly affected children aged 1–4 years, with cough and fever as the principal clinical manifestations, whereas physical examination findings could be unremarkable. Alveolar infiltration was the most common radiographic finding. Elevated LDH levels and lung ultrasound may provide useful adjunctive information for assessing pulmonary parenchymal involvement. Most patients responded favorably to macrolide therapy; however, close monitoring of treatment response is essential to enable timely modification of the antibiotic regimen in patients who fail initial therapy.
Keywords
Pneumonia, Mycoplasma pneumoniae, children, macrolide, clinical features, paraclinical features, treatment outcomes
Article Details
References
2. Jung Yeon Shim (2022). Current perspective on atypical pneumonia in children. Clinical and Experimental Pediatrics, 65(1), 1–9.
3. Meyer Sauteur PM, Beeton ML, et al. (2023). Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions. Lancet Microbe. doi:10.1016/S2666-5247(23)00344-0.
4. Phan Thị Thu Minh, Nguyễn Ngọc Sáng, Lê Thị Hồng Hanh, et al. (2024). Đặc điểm lâm sàng, xét nghiệm và kết quả điều trị viêm phổi do Mycoplasma pneumoniae ở trẻ em. Tạp chí Y học Việt Nam, 539(3), 30–34.
5. Ngô Thị Huyền Trang, Nguyễn Thị Hà, Nguyễn Sỹ Đức, et al. (2025). Đặc điểm lâm sàng, cận lâm sàng viêm phổi nhiễm Mycoplasma pneumoniae ở trẻ em tại Bệnh viện Đại học Y Hà Nội. Tạp chí Nghiên cứu Y học, 189(4), 179–186.
6. Nguyễn Thị Thanh Phúc (2024). Kết quả điều trị viêm phổi Mycoplasma pneumoniae mang gen kháng macrolide ở trẻ em. Tạp chí Nghiên cứu Y học, 2024.
7. Bộ Y tế (2014). Hướng dẫn xử trí viêm phổi cộng đồng ở trẻ em. Quyết định số 101/QĐ-BYT. Nhà xuất bản Y học, Hà Nội.
8. Đặng Mai Liên, Lê Thị Hồng Hanh, Hoàng Thị Thu Hằng, et al. (2023). Đặc điểm dịch tễ học lâm sàng và một số yếu tố liên quan tới viêm phổi nặng do Mycoplasma pneumonia ở trẻ em. Tạp chí Nhi khoa, 16(5), 1–8.